BTI
ACAD icon

Blue Trust Inc’s Acadia Pharmaceuticals ACAD Stock Holding History

Blue Trust Inc’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14
Closed -$299 – 2533
2025
Q3 		$299 Hold
14
– – ﹤0.01% 2485
2025
Q2 		$302 Sell
14
-530
-97% -$9.85K ﹤0.01% 2360
2025
Q1 		$9.04K Hold
544
– – ﹤0.01% 1935
2024
Q4 		$9.98K Sell
544
-210
-28% -$3.39K ﹤0.01% 1867
2024
Q3 		$12.3K Buy
754
+411
+120% +$6.86K ﹤0.01% 2117
2024
Q2 		$6.34K Buy
+343
New +$5.54K ﹤0.01% 2108
2024
Q1 		– Sell
-155
Closed -$3K – 2157
2023
Q4 		$3K Buy
+155
New +$3.7K ﹤0.01% 1973
2023
Q1 		– Sell
-55
Closed -$1K – 2267
2022
Q4 		$1K Buy
55
+3
+6% +$47 ﹤0.01% 1995
2022
Q3 		$1K Buy
52
+40
+333% +$648 ﹤0.01% 1867
2022
Q2 		$0 Buy
+12
New +$224 ﹤0.01% 1878

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Blue Trust Inc's ACAD Position: Q4 2025 in Review

Blue Trust Inc sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 14 shares — an estimated $299 sold.

Blue Trust Inc first reported a position in ACAD in Q2 2022 and held it in 10 quarters. The position peaked at $12.3K in Q3 2024. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Blue Trust Inc reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Blue Trust Inc sold 14 Acadia Pharmaceuticals shares in Q4 2025, an estimated $299.
  • Blue Trust Inc first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Blue Trust Inc's Acadia Pharmaceuticals position peaked at $12.3K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Blue Trust Inc's 13F filing for Q4 2025, filed 16 Jan 2026.